ES2656189T3 - Formas sólidas de un inhibidor macrocíclico de quinasa - Google Patents
Formas sólidas de un inhibidor macrocíclico de quinasa Download PDFInfo
- Publication number
- ES2656189T3 ES2656189T3 ES14736454.1T ES14736454T ES2656189T3 ES 2656189 T3 ES2656189 T3 ES 2656189T3 ES 14736454 T ES14736454 T ES 14736454T ES 2656189 T3 ES2656189 T3 ES 2656189T3
- Authority
- ES
- Spain
- Prior art keywords
- ppm
- crystalline
- values
- peaks
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361840703P | 2013-06-28 | 2013-06-28 | |
| US201361840703P | 2013-06-28 | ||
| PCT/IB2014/062296 WO2014207606A1 (en) | 2013-06-28 | 2014-06-17 | Solid forms of a macrocyclic kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2656189T3 true ES2656189T3 (es) | 2018-02-26 |
Family
ID=51136530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14736454.1T Active ES2656189T3 (es) | 2013-06-28 | 2014-06-17 | Formas sólidas de un inhibidor macrocíclico de quinasa |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9637500B2 (https=) |
| EP (1) | EP3013835B1 (https=) |
| JP (1) | JP6110817B2 (https=) |
| AR (1) | AR096759A1 (https=) |
| CA (1) | CA2916605C (https=) |
| ES (1) | ES2656189T3 (https=) |
| TW (1) | TW201504246A (https=) |
| WO (1) | WO2014207606A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10159663B2 (en) * | 2014-08-20 | 2018-12-25 | Teligene Ltd. | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| EP3798222B1 (en) | 2015-07-31 | 2023-11-22 | Pfizer Inc. | Crystalline form of lorlatinib free base |
| CA3000386A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
| EP3415518B1 (en) | 2016-03-03 | 2020-07-08 | Shenzhen TargetRx, Inc. | Macrocycle and composition comprising thereof |
| EP3440086B1 (en) * | 2016-04-08 | 2020-08-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| JP7153069B2 (ja) | 2017-10-10 | 2022-10-13 | ファイザー・インク | ロルラチニブ遊離塩基水和物の結晶形態 |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| US20210163498A1 (en) | 2018-04-23 | 2021-06-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| US12077528B2 (en) | 2018-11-28 | 2024-09-03 | Shenzhen Targetrx, Inc. | Preparation method for deuterated macrocyclic compound |
| CN109651398B (zh) * | 2019-01-25 | 2021-07-30 | 安庆多辉生物科技有限公司 | 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法 |
| EP3999514A1 (en) | 2019-07-18 | 2022-05-25 | Pliva Hrvatska D.O.O. | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| CN110483551B (zh) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | 一种劳拉替尼游离碱的晶体 |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| IL297832A (en) | 2020-05-05 | 2023-01-01 | Nuvalent Inc | Macrocyclic heteroaromatic chemotherapeutic agents |
| KR102698413B1 (ko) | 2020-05-05 | 2024-08-26 | 뉴베일런트, 아이엔씨. | 헤테로방향족 거대환식 에터 화학치료제 |
| CN112724077B (zh) * | 2020-12-29 | 2023-07-11 | 武汉利昌医药科技有限公司 | 一种劳拉替尼中间体的合成方法 |
| CN113292496B (zh) * | 2021-05-17 | 2023-03-10 | 安徽联创生物医药股份有限公司 | 一种劳拉替尼中间体的合成方法 |
| IL311444A (en) | 2021-10-01 | 2024-05-01 | Nuvalent Inc | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2566858A2 (en) | 2010-05-04 | 2013-03-13 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| HUE034118T2 (en) | 2012-03-06 | 2018-01-29 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
-
2014
- 2014-06-17 CA CA2916605A patent/CA2916605C/en active Active
- 2014-06-17 ES ES14736454.1T patent/ES2656189T3/es active Active
- 2014-06-17 US US14/898,582 patent/US9637500B2/en active Active
- 2014-06-17 EP EP14736454.1A patent/EP3013835B1/en not_active Not-in-force
- 2014-06-17 WO PCT/IB2014/062296 patent/WO2014207606A1/en not_active Ceased
- 2014-06-18 JP JP2014124999A patent/JP6110817B2/ja not_active Expired - Fee Related
- 2014-06-26 AR ARP140102433A patent/AR096759A1/es unknown
- 2014-06-27 TW TW103122400A patent/TW201504246A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2916605A1 (en) | 2014-12-31 |
| EP3013835A1 (en) | 2016-05-04 |
| EP3013835B1 (en) | 2017-12-13 |
| WO2014207606A1 (en) | 2014-12-31 |
| JP6110817B2 (ja) | 2017-04-05 |
| US9637500B2 (en) | 2017-05-02 |
| AR096759A1 (es) | 2016-02-03 |
| TW201504246A (zh) | 2015-02-01 |
| CA2916605C (en) | 2018-04-24 |
| JP2015010091A (ja) | 2015-01-19 |
| US20160115178A1 (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2656189T3 (es) | Formas sólidas de un inhibidor macrocíclico de quinasa | |
| ES2642201T3 (es) | Inhibidores de quinazolina de formas mutantes de activación del receptor del factor de crecimiento epidérmico | |
| US11020376B2 (en) | Crystalline form of lorlatinib free base | |
| ES2853924T3 (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| ES2342660T3 (es) | Nuevas formas cristalinas del compuesto anticancerigeno zd1839. | |
| ES2979111T3 (es) | Polimorfo de macrociclo de diarilo | |
| US9879008B2 (en) | 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof | |
| CA2813607C (en) | Substituted pyridazine carboxamide compounds | |
| ES2819676T3 (es) | Formas cristalinas de maleato de lorlatinib | |
| JP2020503378A (ja) | 三環式ヘテロアリール基含有化合物 | |
| AU2004255934A1 (en) | Isethionate salt of a selective CDK4 inhibitor | |
| ES2863923T3 (es) | Formas cristalinas de la sal mesilato de derivado de piridinilaminopirimidina, métodos de preparación para las mismas, y aplicaciones de las mismas | |
| KR20100085142A (ko) | Ｃ-ｍｅｔ/ｈｇｆｒ 억제제의 다형체 | |
| ES2956847T3 (es) | Método mejorado para la fabricación de 3-[(1s)-1-imidazo[1,2-a]piridin-6-iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimórficas de la misma | |
| JP2007277241A (ja) | （２Ｒ，Ｚ）−２−アミノ−２−シクロヘキシル−Ｎ−（５−（１−メチル−１Ｈ−ピラゾール−４−イル）−１−オキソ−２，６−ジヒドロ−１Ｈ−［１，２］ジアゼピノ［４，５，６−ｃｄ］インドール−８−イル）アセトアミドの多形体 | |
| WO2023204303A1 (ja) | ７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－アミン誘導体の結晶 | |
| KR20130141469A (ko) | 피라졸릴아미노퀴나졸린의 브롬화수소 염 |